Among the most resistant forms of breast cancer, triple-negative disease has long confronted patients and physicians alike with a narrowing corridor of options. Researchers at Mount Sinai have now found that pairing the drug everolimus with standard carboplatin chemotherapy may widen that corridor, cutting the risk of disease progression or death by more than half in a phase 2 trial. The discovery turns on a missing gene — PTEN — whose absence leaves a cellular growth pathway unchecked, and which everolimus is designed to quiet. The finding is preliminary, but in a disease where time and optio
News-Medical.net
· Aug 21, 2025
· health
· 2 min de lectura
High
Verificación: Verificado
Combination therapy shows 52% progression reduction in triple-negative breast cancer
Patients with advanced triple-negative breast cancer, one of the most aggressive breast cancer forms, may benefit from improved treatment options.
◉
Health & Medicine
8252 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% coincidencia
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% coincidencia
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% coincidencia
Cobertura Relacionada
World Socialist Web Site · Aug 22
H5N1 avian flu spreads across Australia with 290 confirmed infections
Australia faces a rapidly spreading H5N1 avian flu outbreak with 290 confirmed infections across all states, threatening…
Devdiscourse · Aug 22 Congo's Bundibugyo Crisis: Health Attacks Threaten Economic Stability Beyond Medical ResponseWHO warns that violence and attacks on health facilities in eastern DRC's Bundibugyo outbreak threaten disease control a…
The Times of India · Aug 22 Reactor blast at Telangana pharma unit kills 2, injures 9A reactor blast at a pharmaceutical unit in Telangana's Yadadri Bhuvanagiri district killed two workers and injured nine…
Google News · Aug 22 Exercise-mimicking weight-loss pill clears first human trialsEnveda's ENV-308, a novel obesity drug designed to replicate exercise's biochemical effects, has successfully completed …
Sesgo y Encuadre
⚖
Medical research article presenting clinical trial results with straightforward reporting of efficacy data and expert commentary, minimal bias detected.
Bias Direction
center
Confidence
HIGH
Standard medical journalism framing: presenting peer-reviewed research findings with supporting expert quotes, scientific context, and mechanism explanation. Uses cautious language ('suggests,' 'should be further tested') appropriate for phase 2 trial results.
one of the most aggressive and hard-to-treat forms
tougher to treat and can be more dangerous
growth switch
Patient testimonials or lived experience perspectives
Cost/accessibility considerations for the combination therapy
Comparison to other emerging TNBC treatments
Potential limitations or criticisms of the study design
Perspectives from patients who may not respond to this treatment
Timeline for potential FDA approval or clinical availability
Impacto Geopolítico
🌎
Medical breakthrough in cancer treatment has no direct geopolitical implications; this is a clinical research finding with potential healthcare policy impacts across developed nations.
Escalation Risk
low
Confidence
HIGH
No geopolitical power dynamics affected. This is a pharmaceutical/medical research development that may influence healthcare competition among pharmaceutical companies and medical institutions globally.
Lente Económico
📈
Mount Sinai study demonstrates 52% progression reduction in triple-negative breast cancer using everolimus-carboplatin combination, potentially expanding treatment options for aggressive cancer subtype affecting 10-15% of breast cancer cases.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical and Biotechnology
Healthcare and Medical Services
Medical Devices and Diagnostics
Health Insurance
Patients with advanced triple-negative breast cancer gain access to potentially more effective treatment option with improved progression-free survival. May reduce overall treatment burden and extend quality of life for affected individuals, though drug costs and insurance coverage remain considerations.
FDA likely to prioritize review pathway for combination therapy approval; healthcare systems may need to update treatment protocols and coverage policies; potential for expanded clinical trial funding; pricing negotiations between manufacturers and payers regarding everolimus combination therapy reimbursement.